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Abstract
Background: Outcomes in younger (<40 years) and elderly (≥70 years) patients with advanced biliary cancer (ABC)
receiving palliative chemotherapy are unclear. This study assessed outcomes in those receiving monotherapy or
combination therapy in thirteen prospective systemic-therapy trials.
Methods: Multivariable analysis explored the impact of therapy on progression-free (PFS) and overall survival (OS)
in two separate age cohort groups: <70 years and ≥70 years, and <40 years and ≥40 years.
Results: Overall, 1163 patients were recruited (Jan 1997-Dec 2013). Median age of entire cohort: 63 years (range 23–85);
36 (3%) were <40, 260 (22%); ≥70. Combination therapy was platinum-based in nine studies. Among patients <40 and
≥70 years, 23 (64%) and 182 (70%) received combination therapy, respectively. Median follow-up was 42 months
(95%-CI 37–51). Median PFS for patients <40 and ≥40 years was 3.5 and 5.9 months (P = 0.12), and OS was 10.8
and 9.7 months, respectively (P = 0.55). Median PFS for those <70 and ≥70 years was 6.0 and 5.0 months (P = 0.53), and
OS was 10.2 and 8.8 months, respectively (P = 0.08). For the entire cohort, PFS and OS were significantly better in those
receiving combination therapy: Hazard Ratio [HR]-0.66, 95%-CI 0.58–0.76, P < 0.0001 and HR-0.72, 95%-CI 0.63–0.82,
P < 0.0001, respectively; and in patients ≥70 years: HR-0.54 (95%-CI 0.38–0.77, P = 0.001) and HR-0.60 (95%-CI 0.43–0.85,
P = 0.004), respectively. There was no evidence of interaction between age and treatment for PFS (P = 0.58, P = 0.66) or
OS (P = 0.18, P = 0.75).
Conclusions: In ABC, younger patients are rare, and survival in elderly patients in receipt of systemic therapy
for advanced disease, whether monotherapy or combination therapy, is similar to that of non-elderly patients,
therefore age alone should not influence decisions regarding treatment.
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Background
Biliary tract cancers are rare and encompass cholangio-
carcinoma, referring to cancers arising in the intrahepa-
tic, perihilar, or distal biliary tree, gallbladder cancer and
carcinoma of the ampulla of Vater [1]. Combination
treatment with cisplatin/gemcitabine is currently consid-
ered standard of care for the treatment of patients with
advanced biliary cancer (ABC), following the results of
the randomised-controlled phase 3 trial, ABC-02, which
reported a progression-free (PFS) and overall survival
(OS) benefit for this combination over gemcitabine alone
in 410 patients with ABC [2].
Comorbidities and age-related organ dysfunction are
more often reported in elderly patients. There is often
uncertainty regarding the benefits and risks of treatment
in this subgroup [3, 4], which in turn may lead to a
reluctance to implement chemotherapy, and particularly
combination therapy, in these patients. Consequently
they tend to represent a minority of those enrolled in
clinical trials. There is thus less evidence to support
treatment of elderly patients with cancer, who make up
the majority of patients with this diagnosis.
For the more common cancers such as lung [5, 6] and
colorectal cancer [7], there have been elderly-specific
randomised-controlled trials and robust age-specific
subgroup analyses of large studies, which provide
guidance on treatment decisions in the clinical setting.
However, there is a dearth of such data for rarer tumours
such as ABC. In a progressively-ageing population,
outcomes in elderly patients with ABC receiving palliative
chemotherapy are unclear and can be a challenging
therapeutic scenario for oncologists.
In addition, younger age may also influence outcomes
in patients with a cancer diagnosis. In patients aged
≤30 years with breast cancer referred for surgery, for
example, it has been reported that there is a greater
chance of having an endocrine-unresponsive tumour
and a significantly worse prognosis than those patients
aged between 31 and 50 years [8]. It has also been
described that younger patients (<40 years) with periph-
eral cholangiocarcinoma had a significantly worse
survival rate than older patients who received surgical
treatment [9]. However, information is lacking on the
influence of age on the outcomes of younger patients
receiving systemic therapy for ABC and so 40 years was
chosen as age cut-off for further analysis based on
publication by Yeh et al. [9].
The American Society of Clinical Oncology recently
developed recommendations to improve evidence
generation in older patients with cancer in response to a
critical need identified by the Institute of Medicine [10].
Hence, the aim of this study was to assess outcomes
(PFS and OS) of receipt of monotherapy versus combin-
ation therapy in younger (<40 years) and elderly patients
(≥70 years) with ABC in ABC-02 and twelve other
prospective trials of systemic therapy.
Seventy years was chosen as the age cut-off for elderly
patients in this study due to the exponential rise in the
prevalence of age-related changes between 70 and
75 years, and that approximately 90% of people demon-
strate clinical signs of ageing by the age of 70 [11].
Methods
Individual patient data from eleven international first-
line clinical trials, and two using targeted therapies
(with one study including eleven and another nine
patients who received one prior line of therapy), in
ABC (The International Biliary Tract Cancer Collaborators
provided approval for the use of this data) were accessed
for analysis (Table 1) [2, 12–23]. All trials were
approved by appropriate research ethics committees
and regulatory authorities and conducted in accordance
with the Declaration of Helsinki. Baseline characteris-
tics analysed included age, gender, Eastern Cooperative
Oncology Group Performance Status (ECOG PS), dis-
ease stage (locally advanced versus metastatic), systemic
therapy (monotherapy or combination). Site of primary
(cholangiocarcinoma, gallbladder or ampulla of Vater),
histology of tumour (adenocarcinoma versus other),
previous therapy, haemoglobin, white blood cell, neu-
trophil count, and bilirubin were analysed and pre-
sented as part of a previous publication [24], where a
model of neutrophils, disease stage, bilirubin, ECOG
PS, haemoglobin, white blood cells, and gender were
prognostic for PFS and OS, whereas age, site of
primary, histology of tumour, previous therapy, and
platelets were not [24]. Interrogation of those patients
receiving combination cisplatin/gemcitabine has also
been extensively analysed previously [24, 25]. The
association between baseline categorical variables and
age was tested using the Chi-squared test.
This study was an exploratory analysis based on
available data. Detection of a specific effect size
(hazard ratio) was not the target, and so power calcu-
lations were not used, as detection of an intended
hazard ratio was not required. Progression-free sur-
vival [time from randomisation to progression or
death, whichever happens first] and OS [time from
randomisation to death] were analysed using Cox
proportional hazards regression. Multivariable analysis
was employed to explore the impact of age and
therapy (monotherapy versus combination) on PFS
and OS in four age cohorts; those <40 years (youn-
ger) versus ≥40 years and non-elderly (<70 years)
versus elderly (≥70 years). The multivariable model
was adjusted for the following variables: gender, ECOG
PS, disease stage, haemoglobin, white blood cell count,
neutrophil count, and bilirubin.
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The Stata, version 14.1, statistical software package
(Stata Corporation, College Station, Texas) was used to
analyse the data.
Results
Patient characteristics
Overall, 1163 patients were recruited (January 1997–
December 2013). Details on prospective studies
included are contained within Table 1. Complete
demographic data for individual trials is available
within respective publications [2, 12–23].
The baseline patient characteristics for all patients are
detailed in Table 2. The median age of the entire cohort
was 63 years (range 23–85); 36 (3%) were <40, 260
(22%) were ≥70 and 18 (2%) were ≥80 years. Baseline
characteristics/therapy received was balanced in all age
Table 1 Details of prospective trials included
Relevant publication Na Age: Median (range) Phase Systemic Therapy
Bekaii-Saab et al. 2011 [12] 28 56 (26–79) II, Non-randomised Selumetinib
Goldstein et al. 2011 [13] 50 59 (39–78) II, Non-randomised Gemcitabine/Cisplatin
Jensen et al. 2012 [14] 46 66 (37–80) II, Non-randomised Gemcitabine/Oxaliplatin/
Panitumumab/Capecitabine
Lassen et al. 2011 [15] 41 61 (35–75) II, Non-randomised Gemcitabine/Oxaliplatin/
Capecitabine
Malka et al. 2014 (BINGO) [16] 150 62 (35–75) II, Randomised Gemcitabine/Oxaliplatin ±
Cetuximab
Moehler et al. 2014 (AIO) [17] 102 64 (36–84) II, Randomised Gemcitabine ± Sorafenib
Okusaka et al. 2010 (BT22) [18] 83 66 (43–80) II, Randomised Gemcitabine ± Cisplatin
Peck et al. 2012 [19] 9 61 (31–83) II, Non-randomised Lapatinib
Rao et al. 2005 [20] 54 57 (36–76) III, Randomised 5-Fluorouracil/Etoposide/
Leucovorin versus Epirubicin/
Cisplatin/5-Fluorouracil
Riechelmann et al. 2007 [21] 75 61 (37–84) II, Non-randomised Gemcitabine/Capecitabine
Ferraro et al. 2016 (TACTIC) [22] 48 64 (40–82) II, Non-randomised Gemcitabine/Cisplatin/
Panitumumab
Valle et al. 2010 (ABC-02) [2] 410 63 (23–85) III, Randomised Gemcitabine ± Cisplatin
Wagner et al. 2009 [23] 72 62 (36–80) II, Non-randomised Gemcitabine/Oxaliplatin/
5-Fluorouracil
aDue to non-availability of some data, 5 patients were not included in overall analysis
Table 2 Distribution of baseline characteristics by age groupa
Covariate <40 years
Total N = 36
N (%)
≥40 years
Total N = 1127
N (%)
P-valueb <70 years
Total N = 903
N (%)
≥70 years
Total N = 260
N (%)
P-valueb
Gender Female 16 (44) 597 (53) 0.31 482 (53) 131 (50) 0.39
Male 20 (56) 530 (47) 421 (47) 129 (50)
ECOG performance status 0 10 (28) 350 (31) 0.59 285 (32) 75 (29) 0.24
1 16 (44) 572 (51) 455 (50) 133 (51)
2 4 (11) 81 (7) 60 (7) 25 (10)
Not available 6 (17) 124 (11) 103 (11) 27 (10)
Disease Stage Locally advanced 9 (25) 295 (26) 0.80 233 (26) 71 (27) 0.43
Metastatic 27 (75) 800 (71) 652 (72) 175 (67)
Not available 0 (0) 32 (3) 18 (2) 14 (5)
Treatment Combination 23 (64) 809 (72) 0.20 650 (72) 182 (70) 0.48
Monotherapy 12 (33) 301 (27) 239 (26) 74 (28)
Not available 1 (3) 17 (2) 14 (2) 4 (2)
ECOG performance status: Eastern Cooperative Oncology Group Performance Status
aDue to rounding, all percentages in Table 2 may not equal 100%. bChi-squared test; performed excluding the category “not available”
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cohorts (Table 2). Combination therapy was platinum-
based in nine studies (N = 679 [58%]).
The median follow-up time for all patients was
42 months (95%-Confidence Interval [CI] 37–51).
Progression-free and Overall Survival
The median PFS for the entire cohort [N = 1163] was
5.8 months (95%-CI 5.5–6.2).
The median PFS for patients aged <40 and
≥40 years was 3.5 (95%-CI 2.9–5.6) and 5.9 months
(95%-CI 5.5–6.4) (P = 0.12) and for those <70 and
≥70 years, 6.0 (95%-CI 5.5–6.4) and 5.0 months
(95%-CI 4.2–6.4), respectively (P = 0.53).
The 6-month PFS rate was 26% (95%-CI 13–41) and
49% (95%-CI 46–52) in the <40 and ≥40 year old cohort,
respectively. The 6-month PFS rate was 50% (46–5253)
and 45% (95%-CI 39–51) in the <70 and ≥70 year old
cohort, respectively.
The median PFS in the entire cohort for those
receiving monotherapy and combination therapy was 4.2
(95%-CI 3.7–5.1) and 6.5 months (95%-CI 6.0–7.1),
respectively (P < 0.0001) (Fig. 1a).
The median OS for the entire cohort was 9.8 months
(95%-CI 9.2–10.5).
The median OS for patients <40 and ≥40 years
was 10.8 (95%-CI 5.4–12.7) and 9.7 months (95%-CI
Fig. 1 Kaplan-Meier estimates of progression-free survival (a) and overall survival (b) in patients with advanced biliary tract cancer who received
monotherapy versus combination therapy
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9.2–10.4) (P = 0.55) and for patients <70 and
≥70 years, 10.2 (95%-CI 9.6–11.1) and 8.8 months
(95%-CI 7.9–9.6), respectively (P = 0.08).
The 6-month OS rate was 60% (95%-CI 42–74) and
71% (95%-CI 68–74) in the <40 and ≥40 year old
cohort respectively. The 6-month OS rate was 72%
(68–74) and 68% (95%-CI 61–73) in the <70 and
≥70 year old cohort, respectively.
The median OS in the entire cohort for those receiv-
ing monotherapy and combination therapy was 8.1
(95%-CI 7.1–8.7) and 10.6 months (95%-CI 9.8–11.4),
respectively (P < 0.0001) (Fig. 1b).
In the entire population, the PFS and OS were signifi-
cantly better in those patients receiving combination
therapy in the individual age groups; ≥40, <70 and
≥70 years, but not in those aged <40 years (Fig. 2).
Similarly, in a sub-analysis of those patients receiving
the cisplatin/gemcitabine combination (N = 297) versus
those receiving gemcitabine alone (N = 258), the PFS
and OS were significantly better in those patients receiv-
ing combination therapy in the individual age groups;
≥40 (both P < 0.001), <70 (P < 0.001 and P = 0.002
respectively) and ≥70 years (P = 0.003 and P = 0.014
respectively), but not in those aged <40 years (P = 0.71
and P = 0.72 respectively).
Prognostic factors
Age was not prognostic for PFS or OS in those receiv-
ing monotherapy (P = 0.49 and P = 0.08 respectively)
or combination therapy (P = 0.67 and P = 0.27
respectively), and there was no evidence of interaction
between age and treatment (monotherapy and combin-
ation therapy) in the <40 and ≥40 years age groups for
PFS (P = 0.58) or OS (P = 0.18) or in the <70 and
≥70 years age groups for PFS (P = 0.66) or OS
(P = 0.75). There was no evidence of an interaction
between tumour location and age on PFS (Interaction
with age model P value: Hilar: P = 0.46, Gallbladder:
P = 0.33, Extrahepatic: P = 0.49, Ampulla of Vater:
P = 0.20) or OS (Hilar: P = 0.53, Gallbladder: P = 0.99,
Extrahepatic: P = 0.60, Ampulla of Vater: P = 0.56).
In the overall population, on multivariable analysis,
PFS was worse in those patients with metastatic
disease versus those with locally advanced disease in
those receiving monotherapy (Hazard Ratio [HR] 1.35,
95%-CI 0.99–1.83, P = 0.06) and combination therapy
(HR 1.42, 95%-CI 1.16–1.75, P = 0.001). Overall sur-
vival was also worse in those patients with metastatic
disease versus those with locally advanced disease in
those receiving monotherapy (HR 1.54, 95%-CI 1.12–2.12,
P = 0.01) and combination therapy (HR 1.41, 95%-CI
1.14–1.74, P = 0.001).
In patients <40 years, ECOG PS was prognostic for
PFS and OS and in patients ≥40 years, stage was
prognostic for PFS, and stage and ECOG PS were
prognostic for OS (Table 3).
In patients <70 years, stage and ECOG PS were
prognostic for PFS and OS; and in patients ≥70 years,
they were prognostic for OS (Table 4).
Discussion
Information is lacking on outcomes of patients with a
diagnosis of ABC who are <40 years receiving palliative
chemotherapy, and as the global population ages, there is
also an increasing focus on the need to evaluate treatment
outcomes in older patients with cancer. No prospective
studies report on the efficacy and safety of palliative
chemotherapy in younger patients with ABC and only a
few studies; none prospective, have reported on efficacy
and safety of palliative chemotherapy in elderly patients
with ABC [26–28]. Although gemcitabine-platinum
doublet therapy is now the most common standard
therapeutic option for patients with ABC [2, 18], there
may be resistance among physicians in general clinical
practice to prescribe combination rather than monother-
apy in an older population due to perceptions of potential
increased toxicity and increased presence of comorbidities.
Age was not prognostic for PFS or OS in those receiv-
ing monotherapy or combination therapy. Progression-
free and OS in patients receiving combination versus
monotherapy were statistically significantly better in
those ≥40 years and in those <70 and ≥70 years in the
entire population and in a sub-group analysis of those
Fig. 2 Hazard ratios (combination versus monotherapy) for
progression-free and overall survival in different age cohorts.
(Adjusted for gender, Eastern Co-operative Oncology Group
performance status, disease stage, haemoglobin, white blood
cell count, neutrophil count, and bilirubin). CI: confidence interval, PFS:
progression-free survival, OS: overall survival
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receiving the cisplatin/gemcitabine combination versus
gemcitabine alone. The small sample size in those
patients <40 years precluded a significant outcome and
may be associated with a relevant bias and so results
may be of limited value in this subgroup. Similar
percentages of patients with locally advanced and
metastatic disease were included within the <40 and
≥40 year subgroups, and so this would not account for
results obtained. No family history was reported in
patient subgroups, but the life-time risk of bile duct
cancers in patients with Lynch syndrome is only
approximately 2% [29], and should not be relevant here.
Given that this was an international collaboration, this
does highlight the rarity of ABC in this age group, at
least in those included in these prospective clinical trials
for ABC [3%] [2, 12–23].
There were only eighteen patients aged ≥80 years,
therefore meaningful subgroup analysis was not possible
and the benefit of combination versus monotherapy
remains unclear in this age cohort. Eastern Cooperative
Oncology Group PS was prognostic for OS in all of the
four age cohorts and the presence of metastatic rather
than locally advanced disease had an adverse prognostic
effect on OS in those ≥40, <70 and ≥70 years, which is
similar to findings from ABC-02 [2].
Limitations of this study are lack of toxicity and co-
morbidity analysis, and consequently the cost of these
toxicities and potential inpatient stays, to the elderly
population, cannot be estimated. However, toxicity data
and treatment duration have been published previously
within individual manuscripts [2, 12–23], and it is un-
likely that patients with significant comorbidities were
included in these prospective studies due to clinical trial
eligibility criteria. Of course, selection bias may then be
inherent in prospective studies, but it has recently been
reported in a large retrospective study that active
therapy, when given, in older patients with ABC, is asso-
ciated with similar survival benefits, irrespective of age
[28]. It has also recently been reported that the survival
advantage of cisplatin/gemcitabine compared to gemci-
tabine alone was not associated with an improvement or
deterioration of quality of life in ABC-02 [30].
Another limiting factor of this analysis was the hetero-
geneity of the treatment given in the included series, but
Table 3 Multivariable analysis for progression-free and overall survival (<40 and ≥40 years)a
Covariate PFS
<40 years
PFS
≥40 years
OS
<40 years
OS
≥40 years
Gender
(reference; female)
Female vs Male HR 0.41 (95%
CI 0.13–1.33,
P = 0.14)
HR 1.02 (95%
CI 0.88–1.18,
P = 0.81)
HR 1.11 (95%
CI 0.38–3.20,
P = 0.85)
HR 1.14 (95%
CI 0.97–1.32,
P = 0.10)
ECOG performance
status (reference; 0)
0 vs 1 HR 4.94 (95%
CI 1.13–21.52)
HR 1.05 (95%
CI 0.89–1.23)
HR 3.59 (95%
CI 0.79–16.37)
HR 1.02 (95%
CI 0.86–1.20)
0 vs 2 HR 15.89 (95%
CI 2.19–115.33)
[P = 0.01]
HR 1.39 (95%
CI 1.04–1.85)
[P = 0.10]
HR 113.11 (95%
CI 7.99–1600.53)
[P = 0.001]
HR 1.87 (95%
CI 1.40–2.50)
[P = 0.0002]
Disease stage
(reference; locally
advanced)
Locally advanced
vs Metastatic
HR 3.17 (95%
CI 0.73–13.77,
P = 0.12)
HR 1.38 (95%
CI 1.17–1.64,
P < 0.001)
HR 4.91 (95%
CI 0.77–31.07,
P = 0.09)
HR 1.40 (95%
CI 1.18–1.68,
P < 0.001)
PFS Progression-free survival, OS Overall survival, ECOG PS Eastern Cooperative Oncology Group Performance Status
aThe multivariable model was adjusted for the following variables; treatment, haemoglobin, white blood cell count, neutrophil count, and bilirubin
Table 4 Multivariable analysis for progression-free and overall survival (<70 and ≥70 years)a
Covariate PFS
<70 years
PFS
≥70 years
OS
<70 years
OS
≥70 years
Gender
(reference; female)
Female vs Male HR 1.00 (95%
CI 0.84–1.18,
P = 0.98)
HR 1.14 (95%
CI 0.83–1.56,
P = 0.42)
HR 1.12 (95%
CI 0.94–1.33,
P = 0.22)
HR 1.33 (95%
CI 0.97–1.84,
P = 0.08)
ECOG performance
status (reference; 0)
0 vs 1 HR 1.10 (95%
CI 0.92–1.32)
HR 0.86 (95%
CI 0.60–1.24)
HR 1.08 (95%
CI 0.90–1.31)
HR 0.81 (95%
CI 0.57–1.16)
0 vs 2 HR 1.58 (95%
CI 1.13–2.20)
[P = 0.04]
HR 1.03 (95%
CI 0.58–1.83)
[P = 0.65]
HR 2.02 (95%
CI 1.45–2.82)
[P = 0.001]
HR 1.84 (95%
CI 1.03–3.28)
[P = 0.02]
Disease stage
(reference; locally
advanced)
Locally advanced
vs Metastatic
HR 1.46 (95%
CI 1.20–1.78,
P < 0.001)
HR 1.21 (95%
CI 0.86–1.69,
P = 0.28)
HR 1.48 (95%
CI 1.20–1.82,
P < 0.001)
HR 1.49 (95%
CI 1.05–2.12,
P = 0.03)
PFS rogression-free survival, OSO verall survival, ECOG PS Eastern Cooperative Oncology Group Performance Status
aThe multivariable model was adjusted for the following variables; treatment, haemoglobin, white blood cell count, neutrophil count, and bilirubin
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the OS data reported for monotherapy and combination
therapy in patients with ABC is not dissimilar within
this study to that reported in ABC-02, and the addition
of chemotherapy or targeted therapy to the established
ABC-02 regimen, or others, has not lead to significant
improvements in survival to date [2, 12–23, 31]. The
shorter PFS reported in the current study in patients re-
ceiving monotherapy and combination therapy may be
attributable to scanning interval variation. In ABC-02,
this was 12 weekly [2], whereas in Okusaka et al. [18],
imaging was performed every 6 weeks [18, 31].
Data on therapy given following completion of re-
spective therapies is not available, but as OS in the dif-
ferent age cohorts was comparable, it is likely that
patients included in these clinical trials were treated
similarly on progression. However, given the rarity of
this diagnosis, this study was a significant effort to ad-
dress the role of systemic therapy in those <40 and
≥70 years in thirteen prospective trials, five of which
were randomised.
Conclusions
In patients with ABC, cautious interpretation of data
is required in relation to monotherapy versus
combination therapy in those patients <40 years, due
to the limited number of patients in this subgroup,
and more study in this age cohort is necessary. Other
age-related co-variables such as primary sclerosing
cholangitis and the potential presence of breast
cancer susceptibility genes 1/2 (BRCA1/2) mutations
may be enriched in those <40 years and may con-
found OS outcomes. Survival in elderly patients
(≥70 years) in receipt of systemic therapy for ABC is
similar to that of non-elderly patients (<70 years),
including significant benefit from combination therap-
ies over monotherapy in the age strata ≥70 years
similar to the overall population. Therefore, age alone
should not dictate decisions on treatment, and thus
elderly patient participation in clinical trials for ABC
is appropriate, acknowledging that this study provides
data on a clinical trial eligible population ≥ 70 years
(e.g. very fit). Comprehensive geriatric assessment
tools [32–34], incorporating an understanding of
older patient’s individual health profiles, their prac-
tical/social needs, and their wishes, rather than just
their chronological age, need to be an integral com-
ponent of the complicated decision-making processes
when deciphering which patients may benefit from
potentially more toxic combination therapy, and should
form a useful adjunct to future elderly patient-focused
therapeutic trials with ABC. The utilisation of assess-
ment tools to better predict tolerance and toxicity to
chemotherapy should also be considered [35–37].
Abbreviations
ABC: Advanced biliary cancer; CI: Confidence interval; ECOG PS: Eastern
Cooperative Oncology Group Performance Status; HR: Hazard ratio;
OS: Overall survival; PFS: Progression-free survival
Acknowledgements
Thank you to all the participating patients and their families. This is a
culmination of work by the International Biliary Tract Cancer
Collaborators (IBTCC).
Funding
ABC-02 was an investigator-initiated study sponsored by University College
London (UCL), funded by Cancer Research UK [CRUK] (funding reference
number C1813/A4853) with gemcitabine provided by Lilly Oncology
(unrestricted grant). Cancer Research UK was not involved in the design of the
current study. They did fund the data collection for ABC-02 and analysis was
performed by Andre Lopes, who is funded by CRUK. They did not have a role
in the interpretation of the data or in writing the manuscript.
BT22 was an Eli Lilly Japan-sponsored trial; Eli Lilly were not involved in the design
of the current study. They did fund the data collection for BT22. They did not
have a role in the analysis, interpretation of the data or in writing the manuscript.
The ABC and TACTIC trials were Australasian Gastro Intestinal Trials Group
trials funded in part by grants from Eli Lilly and Amgen, respectively, and the
AGITG; additional data collection for OS and PFS was investigator-initiated
and supported by the Ministry of Health, Labour, and Welfare, Health Labour
Sciences Research Grant (with data transfer to CR UK & UCL Cancer Trials
Centre (CTC) under a study-specific agreement). The funders were not
involved in the design of the current study. They did fund the data
collection for the ABC, TACTIC and AGITG studies. They did not have a
role in the analysis, interpretation of the data or in writing the manuscript.
JB is partly supported by the UCLH/UCL Biomedical Research Centre. The
funders were not involved in the design of the current study. They did fund
JB whose author contribution is described previously. They did not have a
role in the analysis, interpretation of the data or in writing the manuscript.
AL is supported by a CR UK grant C444/A15953 to the CR UK & UCL CTC.
Cancer Research UK were not involved in the design of the current study.
They did fund the data collection for ABC-02 and analysis was performed
by Andre Lopes, who is funded by CRUK. They did not have a role in the
interpretation of the data or in writing the manuscript.
Availability of data and materials
The International Biliary Tract Cancer Collaborators provided approval for the
use of this data and the data is stored within the Cancer Research UK & UCL
Cancer Trials Centre.
The data that support the findings of this study are available from Cancer
Research UK & UCL Cancer Trials Centre, but restrictions apply to the availability of
these data, which were used under license for the current study, and so are not
publicly available. Data are however available from the authors upon reasonable
request and with permission of Cancer Research UK & UCL Cancer Trials Centre.
Authors’ contributions
All authors have read and approved the final version of this manuscript. A.
Made substantial contributions to conception and design, or acquisition of
data, or analysis and interpretation of data; MMN, JB, AL, HW, DM, LJ, TO, JK,
DW, DC, JS, DG, MM, TBS, JWV. B. Involved in drafting the manuscript and
revising it critically for important intellectual content; MMN, JB, AL, HW, DM,
LJ, TO, JK, DW, DC, JS, DG, MM, TBS, JWV. C. Gave final approval of the
version to be published; MMN, JB, AL, HW, DM, LJ, TO, JK, DW, DC, JS, DG,
MM, TBS, JWV. D. Agreed to be accountable for all aspects of the work;
MMN, JB, AL, HW, DM, LJ, TO, JK, DW, DC, JS, DG, MM, TBS, JWV.
Competing interests
MMN has received honoraria from Pfizer, research funding from NuCana and
SHIRE (previously Baxalta) and travel assistance from Ipsen and Bayer. JB has
received honoraria from Merck Serono, Roche, Sanofi, and Bayer. HW has
received honoraria from Lilly, Merck, Roche, and Celgene, speaker fees from
Merck and Celgene, research funding from Sirtex and Pfizer, and travel
assistance from Merck, Sirtex, Lilly, and Celgene. LJ has received travel and
accommodation funding from Amgen, Roche, and Sanofi. TO receives
honoraria from Chugai Pharmaceutical Co., Ltd., Pfizer Japan, Inc., Novartis
Pharma K.K., Taiho Pharmaceutical Co., Ltd., Merck Serono Co., Ltd., Eli Lilly
McNamara et al. BMC Cancer  (2017) 17:262 Page 7 of 9
Japan K.K., Dainippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Bayer, Ltd.,
FUJI FILM Co., Ltd., and Yakult Honsha Co., Ltd. He also has a consulting or
advisory role with Eli Lilly Japan K.K., Yakult Honsha Co., Ltd., Amgen,
Dainippon Sumitomo Pharma Co., Ltd., Taiho Pharmaceutical Co., Ltd.,
OncoTherapy Science, Inc., Nobelpharma Co., Ltd., Ono Pharmaceutical Co.,
Ltd., Nippon Boehringer Ingelheim Co., Ltd., Nano Carrier Co., Ltd., Chugai
Pharmaceutical Co., Ltd., Novartis Pharma K.K., and Zeria Pharmaceutical Co.,
Ltd. He receives indirect research funding from Chugai Pharmaceutical Co.,
Ltd., Eli Lilly Japan K.K., Eisai Co., Ltd., Novartis Pharma K.K., Shizuoka Industry,
Takeda Bio Development Center Ltd., Yakult Honsha Co., Ltd., OncoTherapy
Science, Inc., Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd.,
Sceti Medical Labo K.K., Nippon Boehringer IngelheimCo., Ltd., Kowa
Company, Ltd., KyowaHakko Kirin Co., Ltd., Merck Serono Co., Ltd., Ono
Pharmaceutical Co., Ltd., Bayer, Ltd., Pfizer Japan, Inc., AstraZeneca K.K., and
Dainippon Sumitomo Pharma Co., Ltd. JK receives research funding from
Astra Zeneca. DW has received honoraria from Roche, Merck Serono, Celgene,
and Taiho. DC receives indirect research funding from AstraZeneca, Amgen,
Celgene, Merck Serono, Sanofi, Merrimack, and Medimmune. JS has received
consultancy fees from Merck and Amgen. DG receives indirect research funding
from Amgen, Celgene, and Pfizer and has stock ownership in Sirtex. MM
receives research funding from Bayer and Lilly. JWV received honoraria in
advisory capacity from Astra Zeneca and research funding from Lilly.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the ethics committee of University College
London. All patients gave written informed consent to participate in
individual trials. All trials were approved by appropriate research ethics
committees and regulatory authorities and conducted in accordance with
the Declaration of Helsinki.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Molecular & Clinical Cancer Sciences, Institute of Cancer
Sciences, The University of Manchester and The Christie NHS Foundation
Trust, Manchester M20 4BX, UK. 2UCL Cancer Institute, London WCIE 6BT, UK.
3Cancer Research UK & UCL Cancer Trials Centre, London WCIE 6BT, UK.
4Imperial Healthcare, London WI2 ONN, UK. 5Institute Gustave Roussy, 94805
Villejuif, France. 6Vejle Hospital, 7100 Vejle, Denmark. 7National Cancer Center
Hospital, Tokyo 104-0045, Japan. 8Princess Margaret Cancer Centre, Toronto
M5G 2M9, Canada. 9Centre Hospitalier Universitaire Vaudois, CH-1011
Lausanne, Switzerland. 10Royal Marsden Hospital, London, UK. 11University of
Sydney, Sydney, NSW 2006, Australia. 12Prince of Wales Clinical School,
University of New South Wales, Sydney, NSW 2052, Australia.
13Universitätsmedizin Mainz, 55122 Mainz, Germany. 14Mayo Clinic, Phoenix,
AZ 85054, USA.
Received: 23 December 2016 Accepted: 5 April 2017
References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin.
2013;63(1):11–30.
2. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A,
Madhusudan S, Iveson T, Hughes S, Pereira SP, et al. Cisplatin plus
Gemcitabine versus Gemcitabine for biliary tract cancer. N Engl J Med. 2010;
362(14):1273–81.
3. Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer
management and decision making, part II. Cancer J. 2005;11(6):461–73.
4. Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer
management and decision making, part I. Cancer J. 2005;11(6):449–60.
5. Camerinin A, Puccetti C, Donati S, Valsuani C, Petrella MC, Tartarelli G,
Puccinelli P, Amoroso D. Metronomic oral vinorelbine as first-line treatment
in elderly patients with advanced non-small cell lung cancer: results of a
phase II trial (MOVE trial). BMC Cancer. 2015;15:359.
6. Cuffe S, Booth CM, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ,
Shepherd FA. Adjuvant chemotherapy for non-small-cell lung cancer in the
elderly: a population-based study in Ontario. Canada J Clin Oncol. 2012;
30(15):1813–21.
7. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D,
Osborne S, Andre N, Waterkamp D, et al. Bevacizumab plus capecitabine
versus capecitabine alone in elderly patients with previously untreated
metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Lancet Oncol. 2013;14(11):1077–85.
8. Yao Y, Cao M, Fang H, Xie J. Breast Cancer in 30-year-old or younger
patients: clinicopathologic characteristics and prognosis. World J Surg
Oncol. 2015;13:38.
9. Yeh CN, Jan YY, Chen MF. Influence of age on surgical treatment of
peripheral cholangiocarcinoma. Am J Surg. 2004;187(4):559–63.
10. Hurria A, Levit LA, Dale W, Mohile SG, Muss HB, Fehrenbacher L,
Magnuson A, Lichtman SM, Bruinooge SS, Soto-Perez-de-Celis E, et al.
Improving the evidence base for treating older adults with cancer:
American Society of Clinical Oncology statement. J Clin Oncol. 2015;
33(32):3826–33.
11. Balducci L, Extermann M. Management of cancer in the older person: a
practical approach. Oncologist. 2000;5(3):224–37.
12. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S,
Balint C, Liersemann R, et al. Multi-Institutional Phase II Study of Selumetinib
in Patients With Metastatic Biliary Cancers. J Clin Oncol. 2011;29(17):2357–63.
13. Goldstein D, Gainford MC, Brown C, Tebbutt N, Ackland SP, van Hazel G,
Jefford M, Abdi E, Selva-Nayagam S, Gebski V, et al. Fixed-dose-rate
gemcitabine combined with cisplatin in patients with inoperable biliary
tract carcinomas. Cancer Chemother Pharmacol. 2011;67(3):519–25.
14. Jensen LH, Lindebjerg J, Ploen J, Hansen TF, Jakobsen A. Phase II marker-
driven trial of panitumumab and chemotherapy in KRAS wild-type biliary
tract cancer. Ann Oncol. 2012;23(9):2341–6.
15. Lassen U, Jensen LH, Sorensen M, Rohrberg KS, Ujmajuridze Z, Jakobsen A.
A phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin
and capecitabine every two weeks in advanced cholangiocarcinomas.
Acta Oncol. 2011;50(3):448–54.
16. Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E,
Fartoux L, Faivre S, Blanc JF, Viret F, et al. Gemcitabine and oxaliplatin with
or without cetuximab in advanced biliary-tract cancer (BINGO): a
randomised, open-label, non-comparative phase 2 trial. The Lancet
Oncology. 2014;15(8):819–28.
17. Moehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs FT, Ebert MP,
Distelrath A, Geissler M, Trojan J, et al. Gemcitabine plus sorafenib versus
gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-
controlled multicentre phase II AIO study with biomarker and serum
programme. Eur J Cancer. 2014;50(18):3125–35.
18. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A,
Nagino M, Kondo S, Nagaoka S, Funai J, et al. Gemcitabine alone or in
combination with Cisplatin in patients with biliary tract cancer: a
comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469–74.
19. Peck J, Wei L, Zalupski M, O'Neil B, Villalona Calero M, Bekaii-Saab T.
HER2/neu may not be an interesting target in biliary cancers: results of an
early phase II study with lapatinib. Oncology. 2012;82(3):175–9.
20. Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J,
Norman AR. Phase III study of 5FU, etoposide and leucovorin (FELV) compared
to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with
advanced biliary cancer. Br J Cancer. 2005;92(9):1650–4.
21. Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ. Expanded phase
II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer.
2007;110(6):1307–12.
22. Ferraro D, Goldstein D, O’Connell RL, Hill ME, Smith D, Daniel F, Ross PJ,
Oates J, Norman AR, et al. TACTIC: a multicentre, open-label, single arm
phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract
cancer. Cancer Chemother Pharmacol. 2016;78(2):361–7.
23. Wagner AD, Buechner-Steudel P, Moehler M, Schmalenberg H, Behrens R,
Fahlke J, Wein A, Behl S, Kuss O, Kleber G, et al. Gemcitabine, oxaliplatin
and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel,
multicentre phase-II trials. Br J Cancer. 2009;101(11):1846–52.
24. Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, Knox J,
Wagner D, Cunningham D, Shannon J, et al. Prognostic factors for
progression-free and overall survival in advanced biliary tract cancer.
Ann Oncol. 2016;27(1):134–40.
McNamara et al. BMC Cancer  (2017) 17:262 Page 8 of 9
25. Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, Bridgewater J,
Okusaka T, et al. Cisplatin and gemcitabine for advanced biliary tract cancer:
a meta-analysis of two randomised trials. Ann Oncol. 2014;25(2):391–8.
26. Kuriyama H, Kawana K, Taniguchi R, Jono F, Sakai E, Ohubo H, Suzuki H,
Kobayashi S, Murata Y, Inamori M, et al. Single-agent gemcitabine in elderly
patients with unresectable biliary tract cancer. Hepato-Gastroenterology.
2011;58(106):270–4.
27. Kou T, Kanai M, Ikezawa K, Ajiki T, Tsukamoto T, Toyokawa H, Yazumi S,
Terajima H, Furuyama H, Nagano H, et al. Comparative outcomes of elderly
and non-elderly patients receiving first-line palliative chemotherapy for
advanced biliary tract cancer. J Gastroenterol Hepatol. 2014;29(2):403–8.
28. Horgan A, Knox J, Aneja P, Le L, McKeever E, McNamara M. Patterns of care
and treatment outcomes in older patients with biliary tract cancer.
Oncotarget. 2015;6(42):44995–5004.
29. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J,
Fishel R, Lindor NM, Burgart LJ, Hamelin R, et al. Revised Bethesda
guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome)
and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.
30. Bridgewater J, Lopes A, Palmer D, Cunningham D, Anthoney A, Maraveyas A,
Madhusudan S, Iveson T, Valle J, Wasan H. Quality of life, long-term survivors
and long-term outcome from the ABC-02 study. Br J Cancer. 2016;
114(9):965–71.
31. Furuse J, Okusaka T, Bridgewater J, Taketsuna M, Wasan H, Koshiji M, Valle J.
Lessons from the comparison of two randomized clinical trials using gemcitabine
and cisplatin for advanced biliary tract cancer. Crit Rev Oncol Hematol.
2011;80(1):31–9.
32. Chaibi P, Magne N, Breton S, Chebib A, Watson S, Duron JJ, Hannoun L,
Lefranc JP, Piette F, Menegaux F, et al. Influence of geriatric consultation
with comprehensive geriatric assessment on final therapeutic decision in
elderly cancer patients. Crit Rev Oncol Hematol. 2011;79(3):302–7.
33. Extermann M, Hurria A. Comprehensive geriatric assessment for older
patients with cancer. J Clin Oncol. 2007;25(14):1824–31.
34. Kenis C, Bron D, Libert Y, Decoster L, Van Puyvelde K, Scalliet P, Cornette P,
Pepersack T, Luce S, Langenaeken C, et al. Relevance of a systematic
geriatric screening and assessment in older patients with cancer: results of a
prospective multicentric study. Ann Oncol. 2013;24(5):1306–12.
35. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM,
Gajra A, Bhatia S, Katheria V, et al. Predicting chemotherapy toxicity in older
adults with cancer: a prospective multicentre study. J Clin Oncol. 2011;29(25):
3457–65.
36. Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, Feng T, Smith D,
Sun CL, De Glas N, et al. Validation of a prediction tool for chemotherapy
toxicity in older adults with cancer. J Clin Oncol. 2016;34(20):2366–71.
37. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, Levine RM,
Lubiner ET, Reyes P, Schreiber 3rd FJ, et al. Predicting the risk of
chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment
Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–86.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
McNamara et al. BMC Cancer  (2017) 17:262 Page 9 of 9
